Global Hepatitis B Treatment Market - 2023-2030

Global Hepatitis B Treatment Market - 2023-2030

Global Hepatitis B Treatment Market reached US$ 4.4 billion in 2022 and is expected to reach US$ 5.9 billion by 2030 growing with a CAGR of 3.8% during the forecast period 2023-2030. The global Hepatitis B treatment market is trending towards current and innovative modalities for the management of chronic Hepatitis B infection.

For instance, according to the World Journal of Hepatology, published on May 27, 2023, Novel therapies may enable effective control of Chronic Hepatitis B. Direct-acting antivirals and immunomodulators are among them. Reducing viral antigen load is critical for the success of immune-based treatments. Immunomodulatory therapy may cause the host immune system to be modulated. It may boost/restore innate immunity against HBV (as a toll-like receptor and cytosolic retinoic acid-inducible gene I agonist).

Others may induce adaptive immunity as checkpoint inhibitors, therapeutic HBV vaccines including protein (HBsAg/preS and Hepatitis B core antigen), monoclonal or bispecific antibodies, and genetically engineered T cells to generate chimeric antigen receptor-T or T-cell receptor-T cells and HBV-specific T cells to efficiently clear HBV. Combination therapy may successfully overcome immunological tolerance and lead to HBV control and cure.

Hepatitis B is an infectious virus that impacts the liver, causing inflammation of the liver tissues and possible long-term damage. This disease is most commonly spread by exposure to infected bodily fluids. Symptoms include yellowing of the eyes, stomach pain, and dark urine. Some people, particularly children, show no symptoms. Chronic cases can result in liver failure, malignancy, or scarring.

The condition often clears up on its own. Chronic cases require medication, including immune modulator drugs, antiviral drugs, vaccines, and possibly a liver transplant. Furthermore, the high prevalence of Hepatitis B, increasing funding for Hepatitis B drugs, and evolving clinical trials are the factors expected to drive the market over the forecast period.

Market Dynamics

The Increasing Awareness and Rising Funding for Hepatitis B-Related Public Health Services are the Factors Expected to Drive the Global Hepatitis B Treatment Market Growth.

On June 5, 2023, the Hepatitis B Foundation (HBF) is announcing the forecasting of the Hep B United (HBU) 2023 Mini-Grant Program awards for expanding Hepatitis B-related public health services in the United States.

HBF will award up to 7 grants ranging from $5,000 to $10,000 each. The purpose of this program is to enhance the capacity of HBU coalition partners to conduct Hepatitis B education, prevention, testing, and linkage to care in local communities. The emphasis of this grant is focused on addressing Hepatitis B among African Immigrants, Asian American, Native Hawaiian, and Pacific Islander communities, and Persons Who Use Drugs.

This mini-grant forecast supports activities at the local coalition level to advance the Hepatitis B priority areas of the U.S. Department of Health and Human Services Viral Hepatitis National Strategic Plan. Thus, owing to the above factors, the market is expected to drive over the forecast period.

The Increasing Clinical Trials for Chronic Hepatitis Drugs are Expected to Drive the Global Hepatitis B Treatment Market.

According to ClinicalTrials.Com, ImmuneMed, Inc. initiated an interventional phase IIa multi-center, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of oral antiviral agents/hzVSF-v13 combination therapy vs oral antiviral monotherapy in chronic Hepatitis B patients on January 11, 2022. The study is expected to be completed on December 4, 2024.

Similarly, on April 15, 2022, Istanbul University - Cerrahpasa (IUC) conducted an interventional study on the influence of education on oral antiviral usage on medication compliance and quality of life in patients with the hepatitis-B diagnosis. The study is expected to be completed on December 25, 2022. Thus, owing to the above factors, the market is expected to drive over the forecast period.

High Cost of Hepatitis B Medications is Expected to Hamper the Global Hepatitis B Treatment Market Growth.

According to the Hepatitis B Foundation Report 2022, if an individual does not have insurance or knows how to access Medicaid or Medicare, they may be unable to purchase medication in the United States. The medication would cost them a total of $11,484 if they paid out of pocket. According to one study, low household income and publicly financed health insurance were associated with a lower readiness to accept Hepatitis B treatment.

Moreover, research study conducted in Ghana, the high cost of Hepatitis B management was discovered to be a barrier. According to this survey, the average cost of Hepatitis B medication (Tenofovir) was Ghc 3,600, or $670 per year. The typical Ghanaian salary is approximately Ghc 9,600 or $1,778; hence, the cost of Hepatitis B medicine is approximately 38% of the average Ghanaian income. Thus, from the above factors, the market is expected to hamper over the forecast period.

Russia-Ukraine Conflict Analysis

The Russian-Ukrainian war had an extensive effect on society, including healthcare systems. The violence and its aftermath may impede healthcare infrastructure in affected areas. Damage to medical facilities, shortages of medical supplies and equipment, and displacement of healthcare professionals may make it difficult to provide effective healthcare services, including Hepatitis B treatment.

The displacement of people due to conflict often leads to overpopulation of temporary housing, inadequate sanitation, and limited access to clean drinking water. Poor hygiene conditions and the lack of preventive measures, such as immunization, can result in a heightened risk of contracting infectious diseases like Hepatitis B.

The war may cause population dislocation, limited mobility, and disruption of healthcare services. These circumstances can limit people's capacity to obtain vital healthcare services, such as Hepatitis B diagnosis, treatment, and follow-up care, especially in conflict zones or among displaced populations.

Conflict can disrupt supply chains, making it difficult to obtain and distribute drugs and vaccines, including those used in Hepatitis B treatment. This disruption may cause medicine shortages, affecting the availability and pricing of Hepatitis B treatment alternatives.

Moreover, in conflict-affected areas, healthcare resources may be reallocated to treat emergency medical requirements and trauma-related care. This shift in priority may have an impact on the screening, diagnosis, and management of chronic illnesses such as Hepatitis B, perhaps leading to treatment delays or inadequate disease monitoring. Therefore, taking into account the factors mentioned earlier, it can be stated that the Hepatitis B treatment market experienced a moderate impact as a result of the war.

COVID-19 Impact Analysis:

The COVID-19 pandemic had a negative impact on the global Hepatitis B treatment market owing to the increasing lack of immunizations among other factors. The COVID-19 global pandemic persists to influence healthcare usefulness above those immediately connected to the governance of SARS-CoV-2 transmission and infection including the Hepatitis B vaccine.

Overall multinational disturbance in regular childhood vaccination has influenced a bulk of provinces and nations, particularly in the initial pandemic stages. While data reveal succeeding recovery in vaccination rates, a significant number of vulnerable individuals stay unvaccinated. The downstream influence is estimated to be even more significant in resource-limited environments and economically more inferior inhabitants, and consequently, there are rising matters about the resurgence of vaccine-preventable infections.

For instance, the World Health Organization–designated Western Pacific Region (WPR) and African Region (AFR) hold the most elevated number of chronic Hepatitis B virus (HBV) infections globally. The COVID-19 pandemic has disturbed childhood vaccination, jeopardizing advancement toward the elimination of Hepatitis B by 2030.

Moreover, in sub-Saharan Africa (SSA), immunization rates dropped during COVID-19 across several regular infant vaccines including diphtheria-tetanus-pertussis vaccination dropped by 3.8 %, measles first-dose by 4.4 % and, most strikingly, the first dose of the pentavalent vaccine (including HBV) by 41 %. However, the directions on how to manage vaccination deficits are known and continue to mature, highlighting the significance of conserving and fixing regular vaccinations and essential mass immunization drives during and post-pandemics.

Segment Analysis

The global Hepatitis B treatment market is segmented based on type, treatment, distribution channel, and region.

Online Pharmacies from the Distribution Channel Segment Account for 25.2% of the Market Share Owing to the Availability of Assistance Programs for Medications, Increased Internet Penetration, and Growing E-commerce Awareness.

Online pharmacy uses the Internet to send orders to customers via mail, shipping firms, online pharmacy web portals, and other methods. It's also known as a mail-order pharmacy or an internet pharmacy.

Some of the primary reasons driving market expansion are increased internet penetration globally, particularly in developing nations, improved healthcare infrastructure, global population aging, and growing e-commerce awareness among users. One of the primary aspects driving online pharmacy growth is a shift in consumer behavior, combined with a rising need for convenience. In addition, increased e-commerce and digital technology usage in the healthcare industry are likely to drive market growth in the future years.

Furthermore, there are patient assistance programs in the United States that can aid some people with their medical expenses. This discounted pricing is provided by internet pharmacies, co-pay assistance cards, or pharmaceutical firms. For instance, DiRx, a new online pharmacy, has added two front-line drugs for chronic Hepatitis B infection - generic Viread (Tenofovir) and generic Baraclude (Entecavir) - and will be offering the products at significantly reduced costs. Entecavir 30-count supply will be $33 and Tenofovir $21, respectively, compared to the average retail price of $1,188.

Patients should go to DiRxHealth.com and enter the coupon code HBFSAVE to get Tenofovir or Entecavir at a lower price. Any Hepatitis B patient with a valid U.S. prescription will be able to order and receive free U.S. shipping, with no pre-qualifications or health insurance required.

Similarly, RxOutreach is another online pharmacy that offers low-cost tenofovir and entecavir, and they recently offered a special offer for free medication for up to a year. Gilead offers a patient assistance program for Vemlidy patients in the United States who meet certain conditions. Patient Advocate Foundation and Prescription Hope provide co-pay help programs for eligible persons with insurance who cannot afford their insurance co-pays. Thus, owing to the above factors, the market segment is expected to hold the largest market share over the forecast period.

Geographical Analysis

North America Accounted for Approximately 39.1% of the Market Share Owing to the Availability of Vaccines, High Health Expenditure, and Growing Clinical Trials

According to Dynavax Report 2023, the HEPLISAV-B vaccine is the first and only adult Hepatitis B vaccine approved in the U.S., the European Union, and Great Britain that enables series completion with only two doses in one month. Hepatitis B vaccination is universally recommended for adults aged 19-59 in the U.S. The market share of HEPLISAV-B within Integrated Delivery Networks (IDNs) and Clinics has risen to around 49%, a significant increase from approximately 33% by the end of the first quarter of 2022.

Moreover, on May 9, 2023, HOOKIPA Pharma Inc., a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, announced that the first person has been dosed in a Gilead-led Phase 1 clinical trial of HB-400, an investigational therapeutic vaccine for chronic Hepatitis B. HB-400 is one of two novel compounds being developed in collaboration with Gilead.

Thus, from the above factors, the North American region is expected to hold the largest market share over the forecast period.

Competitive Landscape

The major global players in the market include Bristol-Myers Squibb, Gilead Sciences, Inc., GlaxoSmithKline, Accord Healthcare Inc., Apotex Corp., Arbutus Biopharma, Arrowhead Pharma, Aurobindo Pharma Limited, Lupin Pharmaceuticals Inc., and Merck & Co. Inc., among others.

Why Purchase the Report?
• To visualize the global Hepatitis B treatment market segmentation based on type, treatment, distribution channel, and region, as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of Hepatitis B treatment market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as Excel consisting of key products of all the major players.

The global Hepatitis B treatment market report would provide approximately 69 tables, 68 figures, and 195 Pages.

Target Audience 2023
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies